Monetary value refers to the entity estimate currently projected expenditures.

No definition available.

Name:	cytr_CurrentlyProjectedExpendituresForClinicalPrograms
Namespace Prefix:	cytr_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent the estimated projected expenditure.

+ References

No definition available.

+ Details

Name:	cytr_EstimatedProjectedExpenditureLineItems
Namespace Prefix:	cytr_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash
-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash Equivalents
-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name:	us-gaap_CashAndCashEquivalentsAtCarryingValue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(2))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name:	us-gaap_DebtInstrumentMaturityDate
Namespace Prefix:	us-gaap_
Data Type:	xbrli:dateItemType
Balance Type:	na
Period Type:	duration

- Definition

The cash inflow from the additional capital contribution to the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3255-108585

+ Details

Name:	us-gaap_ProceedsFromIssuanceOfCommonStock
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3291-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name:	us-gaap_RepaymentsOfLongTermDebt
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=cytr_NantCellIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=cytr_HerculesTechnologyGrowthCapitalIncAndHerculesTechnologyIIILPMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis=cytr_AldoxorubicinMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis=cytr_OtherProgramsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis=cytr_GeneralOperationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis=cytr_OtherGeneralAndAdministrativeExpensesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis=cytr_InterestAndTermLoanPaymentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Liquidity and Capital Resources (Details) - USD ($)			2 Months Ended	6 Months Ended
Liquidity and Capital Resources (Details) - USD ($)	Jul. 28, 2017	Jul. 27, 2017	Sep. 30, 2017	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
Estimated Projected Expenditure [Line Items]
Cash and cash equivalents				$ 54,972,846	$ 55,913,199	$ 56,959,485	$ 22,261,372
Debt instrument, repayment of principal and unpaid interest				2,427,362	$ 0
Currently projected expenditures for clinical programs				35,600,000
NantCell, Inc [Member]
Estimated Projected Expenditure [Line Items]
Purchase of common stock				$ 13,000,000
NantCell, Inc [Member] \| Subsequent Event [Member]
Estimated Projected Expenditure [Line Items]
Purchase of common stock		$ 13,000,000
Maturity date of amended loan servicing agreement		Aug. 01, 2018
Hercules Technology Growth Capital, Inc. and Hercules Technology III, L.P. [Member]
Estimated Projected Expenditure [Line Items]
Maturity date of amended loan servicing agreement				Feb. 01, 2020
Hercules Technology Growth Capital, Inc. and Hercules Technology III, L.P. [Member] \| Subsequent Event [Member]
Estimated Projected Expenditure [Line Items]
Debt instrument, repayment of principal and unpaid interest	$ 5,000,000	$ 5,000,000
Hercules Technology Growth Capital, Inc. and Hercules Technology III, L.P. [Member] \| Scenario, Forecast [Member]
Estimated Projected Expenditure [Line Items]
Debt instrument, repayment of principal and unpaid interest			$ 5,000,000
Aldoxorubicin [Member]
Estimated Projected Expenditure [Line Items]
Currently projected expenditures for clinical programs				$ 4,700,000
Other Programs [Member]
Estimated Projected Expenditure [Line Items]
Currently projected expenditures for clinical programs				3,700,000
General Operation [Member]
Estimated Projected Expenditure [Line Items]
Currently projected expenditures for clinical programs				1,100,000
Other General and Administrative Expenses [Member]
Estimated Projected Expenditure [Line Items]
Currently projected expenditures for clinical programs				9,400,000
Interest and Term Loan Payment [Member]
Estimated Projected Expenditure [Line Items]
Currently projected expenditures for clinical programs				$ 16,600,000